EC Paediatrics

Covid-19 is generally very mild in children but a very small percentage may get severe disease. A severe form of disease occurs 2 - 4 weeks post onset of Covid-19 which has many of the features of Kawasaki’s disease has been described and termed multisystem inflammatory syndrome in children. The question that arises is whether we need another syndrome to a Covid-19 complication arising post infection which has many of the clinical features of Kawasaki’s disease. The development of DIC early in the onset of Covid-19 infection in children has not been reported before. We report here for the first time a child presenting with Covid-19 infection associated with gastrointestinal bleeding and DIC features. We propose that MIS-C should be renamed Kawasaki’s disease induced by Covid-19.

Keywords: Covid-19; Disseminated Intravascular Coagulation (DIC); Paediatric; Multisystem Inflammatory Syndrome (MIS-C); Kawasaki’s Disease; Vasculitis

1. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. The Journal of the American Medical Association13 (2020): 1239-1242.
2. Giani T., et al. “COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country”. Pediatric Rheumatology 18 (2020): 35.
3. Toubiana J., et al. “Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study”. British Medical Journal (2020).
4. Whittaker E., et al. “PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2”. The Journal of the American Medical Association3 (2020): 259-269.
5. Toubiana J., et al. “Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study”. British Medical Journal 369 (2020): m2094.
6. Feldstein LR., et al. “Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in US children and adolescents”. The New England Journal of Medicine4 (2020): 334-346.
7. Belot A., et al. “SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020”. Euro Surveillance22 (2020).
8. Dufort EM., et al. “New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York state”. The New England Journal of Medicine4 (2020): 347-358.
9. Chikanza IC., et al. “Disseminated intravascular coagulation as a possible cause of death in severe measles”. Central African Journal of Medicine 27 (1981): 26-29.
10. Li W., et al. “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus”. Nature 426 (2003): 450-454.
11. Hamming I., et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis”. The Journal of Pathology 203 (2004): 631-637.
12. Channappanavar R., et al. “Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice”. Cell Host and Microbe 19 (2016): 181-193.
13. Hamming I., et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis”. The Journal of Pathology 203 (2004): 631-637.
14. Liu J., et al. “Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients”. Med Rxiv (2020).
15. Zhang Q., et al. “Circulating mitochondrial DAMPs cause inflammatory responses to injury”. Nature 464 (2010): 104-107.